Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
June 05 2023 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will present
a company overview at the Goldman Sachs 44th Annual Global
Healthcare Conference on Monday, June 12, 2023 at 8:00 am PT (11:00
am ET) at the Waldorf Astoria Monarch Beach Resort & Club in
Dana Point, CA.
A live audio webcast of the presentation will be available on
the Investors section of the Company’s website at
www.alnylam.com/events. A replay will be available on the Alnylam
website within 48 hours after each event.
About Alnylam Pharmaceuticals Alnylam Pharmaceuticals
(Nasdaq: ALNY) has led the translation of RNA interference (RNAi)
into a whole new class of innovative medicines with the potential
to transform the lives of people afflicted with rare and prevalent
diseases with unmet need. Based on Nobel Prize-winning science,
RNAi therapeutics represent a powerful, clinically validated
approach yielding transformative medicines. Since its founding 20
years ago, Alnylam has led the RNAi Revolution and continues to
deliver on a bold vision to turn scientific possibility into
reality. Alnylam’s commercial RNAi therapeutic products are
ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI®
(givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which
is being developed and commercialized by Alnylam’s partner,
Novartis. Alnylam has a deep pipeline of investigational medicines,
including multiple product candidates that are in late-stage
development. Alnylam is executing on its “Alnylam P5x25” strategy
to deliver transformative medicines in both rare and common
diseases benefiting patients around the world through sustainable
innovation and exceptional financial performance, resulting in a
leading biotech profile. Alnylam is headquartered in Cambridge, MA.
For more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at @Alnylam, on
LinkedIn, or on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230605005662/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340
Josh Brodsky (Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024